

Behavioral Health Care Symposium 2021

Forward Motion:
Moving a Crisis into Action



Our Race to Health Equity

London Wills, Ph.D., National Policy and Advocacy Director, Health Equity

Ramona Burress, Associate Director of Diversity and Inclusion, Clinical Trial Lead

Special Presentation from our Platinum Sponsor:



1

Johnson & Johnson

Our Race to Health Equity

We aspire to help eradicate racial and social injustice as a public health threat by eliminating health inequities for people of color.

Our Core Values:

- Empathy**
Understanding the people we serve and the people who make up our communities of color in the U.S.
- Care**
Taking the scale of our organization and deploying our resources to support communities who are suffering from health inequities in the U.S.
- Trust**
Building lasting and meaningful partnerships and initiatives that demonstrate our commitment and overall resolve to be a trusted partner with communities of color in the U.S.

Our Commitment to Bold Action:



People First Culture
Cultivate one of the most diverse and inclusive workforces that inspires innovative healthcare solutions around the world.



Healthier Communities
Help close the racial mortality gap by investing in culturally competent community care models that create healthy outcomes for people of color.



Enduring Alliances
Lead and leverage J&J's powerful partnership network to combat racial and social health determinants.

© Janssen Pharmaceuticals, Inc. 2021 July 2021 cp-243602v1

2

Why Representation in Clinical Research Matters

Clinical Trials should mirror patient population demographics

As we enter an era in which the principles of personalized and precision medicine are reshaping healthcare, we now know that without tailoring medical care to all who need it, people will be left behind. Creating more inclusive clinical trials is a critical first step.



Pharmacogenetic research has uncovered significant differences among racial and ethnic groups in the metabolism, effectiveness, and side-effect profiles of many clinically important drugs.¹

Certain diseases and medications may impact people differently based on multiple factors, including ethnicity, gender, age and comorbidities.

Diversity in clinical trials allows us to study an investigational medication in different populations.

We have an ethical obligation to demonstrate the safety and efficacy of our drugs in their intended target populations.

FDA guidance states that clinical trials should proactively seek to enroll patients that reflect the population that will use the medication.

Research
includes me™
Diversity • Equity • Inclusion in Clinical Trials

¹ Burroughs et. al. Racial and Ethnic Differences in Response to Medicines: Towards Individualized Pharmaceutical Treatment. J. Natl. Med. Assoc. 2002, 94, 1-26.

janssen  PHARMACEUTICAL COMPANY OF 